Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes, not weight loss. For weight management, the same molecule is available as Zepbound, which is FDA-approved for chronic weight management. At PEAK, we prescribe Zepbound for weight-loss patients.
The Short Answer
For diabetes: Mounjaro is typically long-term or indefinite—like blood pressure medication.
For weight management: Tirzepatide (as Zepbound) is designed as ongoing therapy. SURMOUNT-4 showed that stopping leads to significant weight regain within months.
Duration for Type 2 Diabetes
Mounjaro for diabetes is prescribed as ongoing treatment without a predetermined endpoint—consistent with how most diabetes medications work. Patients continue as long as it provides glycemic benefit and is tolerated.
Some patients who achieve significant weight loss and lifestyle changes may eventually reduce or discontinue diabetes medications under supervision—but this is the exception.
Duration for Weight Management
Medical guidelines now recognize obesity as a chronic, relapsing condition requiring ongoing treatment. The SURMOUNT trials studied tirzepatide for 72–88 weeks, consistently showing:
- Weight loss continues for approximately 60–72 weeks before plateauing
- Continued medication maintains that weight loss
- Stopping medication leads to weight regain in most patients
This doesn’t mean every patient takes tirzepatide forever—but the clinical reality is that most patients who respond well benefit from continued use.
What Happens When You Stop
The SURMOUNT-4 trial provided definitive data on treatment discontinuation:
- Patients who switched from tirzepatide to placebo after 36 weeks regained a substantial portion of lost weight by week 88
- Patients who continued tirzepatide maintained or continued losing weight
- Appetite returned to pre-treatment levels within weeks of stopping
- Metabolic improvements partially reversed
This pattern reflects biology: when you lose weight, hormonal and metabolic adaptations promote regain. Tirzepatide counteracts these adaptations; remove it, and they reassert themselves.
SURMOUNT-4 Results
| Group | Weight Change (36–88 weeks) | Key Finding |
|---|---|---|
| Continued tirzepatide | Additional -5.5% | Continued losing weight beyond initial phase |
| Switched to placebo | +14.0% regain | Significant weight regain after stopping |
The Long-Term Strategy at PEAK
- Active loss phase (months 1–12): Dose titration, maximum weight loss, intensive lifestyle support
- Stabilization (months 12–18): Weight plateaus, focus on habit building
- Maintenance (ongoing): Continued tirzepatide at maintenance dose, periodic adjustments
Some patients eventually transition to lower maintenance doses. We never pressure patients off medication that’s working.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
